Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine for acute sickle cell crisis pain
NCT02417298Terminated
- Start
- Nov 2015
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, triple-blind trial of ketamine in sickle cell disease (SCD) (2 arms). Primary endpoints: Change in patient's perception of pain and Total number of patients requiring hospital admission. Started Nov 2015; status: terminated.
02
Drugs
ketamine
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT02417298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02417298.